Skip to main content
. 2023 Mar 13;37(5):310–315. doi: 10.1007/s12149-023-01827-y

Table 1.

Patients’ characteristics of the included patients (n = 38). Given are radiopharmaceuticals, tumour types, mean and SD of the activity (MBq) and age (mean)

Radiopharmaceutical Tumour type Activity (MBq) Age (years)
[18F]FDG Lung: 6, lymphoma: 4, ORL: 3, breast: 2 265.6 ± 65.8 67.9
[18F]PSMA-1007 Biochemical recurrence: 13, primary: 2 243.9 ± 14.0 75.5
[68 Ga]Ga-DOTA-TOC SSTR-expressing neuroendocrine tumours: 8 154.1 ± 12.0 65.3